PS694
o,p′-DDD
analytical standard
别名:
1-(2-氯苯基)-1-(4-氯苯基)-2,2-二氯乙烷, o,p′-DDD, 氯苯二氯乙烷, 米托坦
Vasileios Chortis et al.
The Journal of clinical endocrinology and metabolism, 98(1), 161-171 (2012-11-20)
Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on
A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma.
Aditi A Bapat et al.
Pharmacogenomics, 13(11), 1207-1209 (2012-08-28)
Matthias Kroiss et al.
The Journal of clinical endocrinology and metabolism, 97(10), 3495-3503 (2012-07-28)
Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal toxicity of sunitinib. The objective of the study was to determine the antitumor effects of sunitinib in refractory ACC. This was a phase II, open-label trial
Camille Baudry et al.
European journal of endocrinology, 167(4), 473-481 (2012-07-21)
Alternatives to transsphenoidal pituitary surgery may be required in Cushing's disease (CD) as a first- or second-line treatment. Mitotane is a potent anti-cortisolic drug but has been rarely investigated in the treatment of CD. Evaluation of the efficacy and tolerance
F Menaa et al.
Current medicinal chemistry, 19(34), 5854-5862 (2012-09-01)
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with a poor prognosis. Treatment options for advanced ACC are limited. Indeed, radical tumor resection can lead to local or metastatic recurrence, and mitotane (Lysodren(®)), the only recognized adrenolytic drug, offers
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持